Exhibit 99.3
CONTACTS: FOR IMMEDIATE RELEASE
Donald W. Fallon, CFO Donald C. Weinberger
CEPTOR CORPORATION, INC. Andria Pilo-Arena (Media)
(410) 527-9998 Fax (410) 527-9867 WOLFE AXELROD WEINBERGER ASSOC. LLC
dfallon@ceptorcorp.com (212) 370-4500 Fax (212) 370-4505
don@wolfeaxelrod.com
andria@wolfeaxelrod.com
CEPTOR CORPORATION'S PROPRIETARY ORPHAN DRUG DEVELOPMENT
PIPELINE FEATURED IN GENETIC ENGINEERING NEWS
- COMPANY TARGETS CALPAIN INHIBITION IN NEUROMUSCULAR AND NEURODEGENERATIVE
DISEASE INCLUDING MULTIPLE SCLEROSIS AND DUCHENNE'S MUSCULAR DYSTROPHY-
HUNT VALLEY, MD - JULY 13, 2005 -- CEPTOR CORPORATION, INC. (OTC BB: CEPO), a
development-stage biopharmaceutical company focusing on cell targeted
therapeutic products for neuromuscular and neurodegenerative diseases, was
featured in the July issue of GENETIC ENGINEERING NEWS (GEN), the most widely
read bio-industry publication worldwide. The article profiled the company and
its orphan drug development pipeline including NEURODUR for multiple sclerosis
(MS) and MYODUR for Duchenne muscular dystrophy (DMD).
According to William Pursley, Chief Executive Officer of CepTor, "We are
delighted that the GENETIC ENGINEERING NEWS article profiled CepTor and our
unique research efforts in developing therapeutics for multiple sclerosis and
Duchenne muscular dystrophy." Mr. Pursley continued, "We are the only company
developing cell targeted therapeutics that follows an approach recently
highlighted in the NEW ENGLAND JOURNAL OF MEDICINE as it relates to calpain
inhibition."
The NEW ENGLAND JOURNAL OF MEDICINE article focuses on the abnormal
up-regulation of calpain as the culprit in several neuromuscular and
neurodegenerative diseases, including DMD and MS. The CepTor technology includes
compounds that specifically deliver an established calpain inhibitor directly to
muscle and nerve cells.
-----------------------------------
ABOUT CEPTOR
CEPTOR CORPORATION is a development-stage biopharmaceutical company engaged in
the discovery, development, and commercialization of proprietary, cell-targeted
therapeutic products for the treatment of neuromuscular and neurodegenerative
diseases with a focus on orphan diseases. The Company's mission is to increase
the quality and quantity of life of people suffering with these diseases. An
orphan disease is defined in the United States as a serious or life-threatening
disease that affects less than 200,000 people and for which no definitive
therapy currently exists. CepTor Corporation seeks to create an efficient orphan
drug platform by taking advantage of the legislative, regulatory and commercial
opportunities common to these rare diseases. CepTor's primary efforts are
currently being focused on moving its lead product, MYODUR, into phase I/II
clinical trials for Duchenne muscular dystrophy. The Company's broad platform
technology also includes the development of products for multiple sclerosis,
retinal degeneration and epilepsy.
THIS NEWS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS. SUCH STATEMENTS ARE VALID
ONLY AS OF TODAY, AND WE DISCLAIM ANY OBLIGATION TO UPDATE THIS INFORMATION.
THESE STATEMENTS ARE SUBJECT TO KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES THAT
MAY CAUSE ACTUAL FUTURE EXPERIENCE AND RESULTS TO DIFFER MATERIALLY FROM THE
STATEMENTS MADE. THESE STATEMENTS ARE BASED ON OUR CURRENT BELIEFS AND
EXPECTATIONS AS TO SUCH FUTURE OUTCOMES. DRUG DISCOVERY AND DEVELOPMENT INVOLVE
A HIGH DEGREE OF RISK. FACTORS THAT MIGHT CAUSE SUCH A MATERIAL DIFFERENCE
INCLUDE, AMONG OTHERS, UNCERTAINTIES RELATED TO THE ABILITY TO ATTRACT AND
RETAIN PARTNERS FOR OUR TECHNOLOGIES, THE IDENTIFICATION OF LEAD COMPOUNDS, THE
SUCCESSFUL PRECLINICAL DEVELOPMENT THEREOF, THE COMPLETION OF CLINICAL TRIALS,
THE FDA REVIEW PROCESS AND OTHER GOVERNMENT REGULATION, OUR PHARMACEUTICAL
COLLABORATOR'S ABILITY TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE DRUG
CANDIDATES, COMPETITION FROM OTHER PHARMACEUTICAL COMPANIES, PRODUCT PRICING AND
THIRD PARTY REIMBURSEMENT.
